Sign up to save your podcasts
Or
Share Ep. 156 - JPM Highlights & Alzheimer's Takeaways
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ep. 156 - JPM Highlights & Alzheimer's Takeaways
A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.
Reach us by sending a text
View all episodes
By BioCentury
4.8
3232 ratings
A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.
Reach us by sending a text
More shows like BioCentury This Week
View all
Freakonomics Radio
32,333 Listeners
Bloomberg Intelligence
404 Listeners
Odd Lots
2,001 Listeners
Nature Podcast
762 Listeners
The Long Run with Luke Timmerman
123 Listeners
The Readout Loud
340 Listeners
Making Sense
69 Listeners
Thoughts on the Market
1,312 Listeners
Biotech 2050 Podcast
62 Listeners
Business Of Biotech
86 Listeners
MIT Technology Review Narrated
265 Listeners
Biotech Hangout
19 Listeners
WSJ's Take On the Week
144 Listeners
The Top Line
16 Listeners
The BioCentury Show
11 Listeners